Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

Autor:	Gwen Wilkie, Clare Taylor, Anthony J. Swerdlow, Dorothy H. Crawford, Dilani Dombagoda, Parvez Murad, Kate M Britton, Tanzina Haque, Peter Amlot, Angela Iley
Rok vydání:	2002
Předmět:	Epstein-Barr Virus Infections Herpesvirus 4 Human medicine.medical_treatment Spontaneous remission Antibodies Viral medicine.disease_cause Herpesviridae HLA Antigens hemic and lymphatic diseases Humans Transplantation Homologous Cytotoxic T cell Medicine Child business.industry Histocompatibility Testing Immunosuppression Organ Transplantation General Medicine Immunotherapy Middle Aged medicine.disease Epstein–Barr virus Lymphoproliferative Disorders Lymphoma Transplantation Treatment Outcome Child Preschool Immunology business T-Lymphocytes Cytotoxic
Zdroj:	The Lancet. 360:436-442
ISSN:	0140-6736
DOI:	10.1016/s0140-6736(02)09672-1
Popis:	Summary Background Epstein-Barr virus (EBV)-associated posttransplantation lymphoproliferative disease (PTLD) is a common, often fatal, complication of bone-marrow and solidorgan transplantation. Since tumour growth results from inadequate T-cell control of latent EBV, new immunotherapeutic approaches to treatment are being pioneered. Methods In a phase 1/2 trial, eight patients with progressive PTLD unresponsive to conventional treatment were given one to six infusions of partly HLA-matched allogeneic EBV-specific cytotoxic T lymphocytes (CTLs) from a frozen bank of CTLs derived from healthy blood donors. Findings Of the five patients who completed treatment, three had complete remission and two had no clinical response. One patient partly responded after two infusions. No graftversus-host disease or allo-specific antibodies were detected, and graft function improved in three cases. Tumour responses were mainly seen in those with early, localised, polyclonal disease. EBV load in peripheral blood fell to undetectable levels in all patients who responded to treatment, but was more variable in those who did not. Interpretation Treatment of EBV-associated PTLD with partly HLA-matched CTLs grown from unrelated donors is effective. Spontaneous remission is very unlikely to account for tumour regression in our patients; however, a larger, controlled trial is needed to assess this treatment further. The frozen bank of allogeneic CTLs is less prohibitively labour intensive and expensive for wide scale use than treatment with autologous CTLs. Such banks could be established to treat other infectious and neoplastic diseases in many patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00df52f97b9923bd4c47dffab95574a1 https://doi.org/10.1016/s0140-6736(02)09672-1 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.